Abstract
Background Access to comprehensive diagnostics and novel anti-tuberculosis medicines is crucial to improve tuberculosis control at times of emerging Mycobacterium tuberculosis drug resistance.
Methods We investigated access to genotypic and phenotypic M tuberculosis drug susceptibility testing (DST), availability of anti-tuberculosis drugs and calculated cost of drugs and treatment regimens at major tuberculosis treatment centers in countries of the World Health Organization (WHO) European region. Results are stratified by middle and high-income countries.
Results Overall, 43 treatment centers in 43 countries participated in the study. Phenotypic DST was available for WHO group A drugs levofloxacin/moxifloxacin, bedaquiline and linezolid, in 75%/82%, 48%, and 72% of countries, respectively. Overall, 84% and 56% of countries had access to bedaquiline and delamanid, while only 14% had access to rifapentine. Median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant tuberculosis (shorter regimen, including bedaquiline for six months) and pre-extensively drug-resistant tuberculosis (including delamanid) were €44, €764 and €7 094 in middle income countries (n=12), and €280, €29 765, €207 035 in high income countries (n=29).
Conclusion Tuberculosis control in Europe is limited by widespread lack of DST capacity to new and re-purposed drugs, lack of access to essential medications and high treatment cost for drug-resistant tuberculosis.
Evidence before this study Availability and access to anti-tuberculous treatment are essential for optimal treatment outcomes. Newly developed drugs like bedaquiline have demonstrated an enormous potential to improve outcomes, in particular for the treatment of drug-resistant tuberculosis. However, data on availability and cost of tuberculosis drugs and regimens are scarce. We searched PubMed for original research that reported the cost of anti-tuberculosis drugs and regimens across multiple countries in the WHO European region since Jan 1, 2012. The Pubmed search ((cost[MeSH Major Topic]) AND (tuberculosis[MeSH Major Topic]) AND [(treatment[MeSH Major Topic]) OR (drug[MeSH Major Topic])] AND (“2012/01/01”[Date -Entry] : “3000”[Date - Entry])) did not reveal any comprehensive data on cost of anti-tuberculosis drugs since the introduction of new (bedaquiline, delamanid, pretomanid) and re-purposed drugs in the WHO European region. Recent information on availability of Mycobacterium tuberculosis drug susceptibility testing is limited to a single, laboratory-based survey.
Added value of this study Building on a previous study, performed by the Tuberculosis Network European Trialsgroup (TBnet) in 2013, the current study documents a) the concerning lack of diagnostic capacity of drug susceptibility testing for new and repurposed anti-tuberculosis drugs; b) the lack of availability of adequate regimens for the treatment of multidrug-resistant and (pre-) extensively drug-resistant tuberculosis, in particular in middle income countries; and c) the enormous cost of regimens for the treatment of drug-resistant tuberculosis, in particular in high-income countries.
Implications of all the available evidence The lack of availability of drug-resistance testing in the presence of new and re-purposed drugs bears the high risk of undetected amplification of M tuberculosis drug resistance. In addition, it implies that identification of patients with extensively drug-resistant tuberculosis is currently not possible in many countries in the WHO European region. The cost of drugs and regimens for drug-resistant tuberculosis treatment are very high compared to those for drug-susceptible tuberculosis and highly variable across different countries. Access to adequate treatment regimens for (pre-) extensively drug-resistant tuberculosis is suboptimal.
Rapid upscaling of comprehensive M tuberculosis drug resistance testing and provision of novel anti-tuberculosis drugs are urgently required to provide patients affected by drug-resistant tuberculosis with adequate treatment regimens and prevent the emergence of additional drug resistance in M tuberculosis naturally occurring under insufficient treatments.
Competing Interest Statement
LG is the co-Principal Investigator of two MSF-sponsored clinical trials testing shorter MDR-TB regimens. He has no other competing interests to disclose. The other authors have no conflict of interest to declare with regards to this work.
Funding Statement
CLa is supported by the German Center for Infection Research (DZIF). All other authors have no funding source in the context of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was granted by the Institutional Review Board of Bligny Hospital, France (January 15th, 2020; CRE 2020 01).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
